<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:28:12Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8461687" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8461687</identifier>
        <datestamp>2021-10-08</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="other">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8461687</article-id>
              <article-id pub-id-type="pmcid">PMC8461687</article-id>
              <article-id pub-id-type="pmc-uid">8461687</article-id>
              <article-id pub-id-type="pmid">34556520</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2021-055039</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2021-055039</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Anaesthesia</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1682</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Evaluating the efficacy of intranasal oxytocin on pain and function among individuals who experience chronic pain: a protocol for a multisite, placebo-controlled, blinded, sequential, within-subjects crossover trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-67991478" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0927-0712</contrib-id>
                  <name>
                    <surname>Rash</surname>
                    <given-names>Joshua A.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-77066272" contrib-type="author">
                  <name>
                    <surname>Campbell</surname>
                    <given-names>Tavis S.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-56639580" contrib-type="author">
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Lynn</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-71327696" contrib-type="author">
                  <name>
                    <surname>Flusk</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-80859759" contrib-type="author">
                  <name>
                    <surname>MacInnes</surname>
                    <given-names>Aaron</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-89886871" contrib-type="author">
                  <name>
                    <surname>Nasr-Esfahani</surname>
                    <given-names>Maryam</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-89867382" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0620-3872</contrib-id>
                  <name>
                    <surname>Mekhael</surname>
                    <given-names>Anastasia A.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-62288273" contrib-type="author">
                  <name>
                    <surname>Poulin</surname>
                    <given-names>Patricia A.</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                  <xref rid="aff9" ref-type="aff">9</xref>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib id="author-89886875" contrib-type="author">
                  <name>
                    <surname>Robert</surname>
                    <given-names>Magali</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-66607591" contrib-type="author">
                  <name>
                    <surname>Yi</surname>
                    <given-names>Yanqing</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Psychology, Faculty of Science</institution>, <institution>Memorial University of Newfoundland</institution>, <addr-line content-type="city">St. John’s</addr-line>, <addr-line content-type="state">Newfoundland</addr-line>, <country>Canada</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Psychology, Faculty of Arts</institution>, <institution>University of Calgary</institution>, <addr-line content-type="city">Calgary</addr-line>, <addr-line content-type="state">Alberta</addr-line>, <country>Canada</country></aff>
              <aff id="aff3"><label>3</label><institution>Canadian Injured Workers Alliance</institution>, <addr-line content-type="city">Thunder Bay</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Anesthesia and Pain Medicine, Faculty of Medicine</institution>, <institution>Memorial University of Newfoundland</institution>, <addr-line content-type="city">St. John’s</addr-line>, <addr-line content-type="state">Newfoundland and Labrador</addr-line>, <country>Canada</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine</institution>, <institution>University of British Columbia</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Department of Anesthesiology, Perioperative and Pain Medicine, Cumming School of Medicine</institution>, <institution>University of Calgary</institution>, <addr-line content-type="city">Calgary</addr-line>, <addr-line content-type="state">Alberta</addr-line>, <country>Canada</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Obstetrics and Gynecology, Cumming School of Medicine</institution>, <institution>University of Calgary</institution>, <addr-line content-type="city">Calgary</addr-line>, <addr-line content-type="state">Alberta</addr-line>, <country>Canada</country></aff>
              <aff id="aff8"><label>8</label><institution>The Ottawa Hospital Research Institute</institution>, <addr-line content-type="city">Ottawa</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">Department of Anesthesiology and Pain Medicine</institution>, <institution>University of Ottawa</institution>, <addr-line content-type="city">Ottawa</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff>
              <aff id="aff10"><label>10</label><institution>The Ottawa Hospital Pain Clinic</institution>, <addr-line content-type="city">Ottawa</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">Community Health and Humanities, Faculty of Medicine</institution>, <institution>Memorial University of Newfoundland</institution>, <addr-line content-type="city">St. John's</addr-line>, <addr-line content-type="state">Newfoundland</addr-line>, <country>Canada</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Joshua A. Rash; <email>jarash@mun.ca</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>11</volume>
              <issue>9</issue>
              <elocation-id>e055039</elocation-id>
              <history>
                <date date-type="received">
                  <day>03</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2021-09-23">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2021-055039.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2021-055039.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2021-055039.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Current treatments for chronic pain (eg, opioids) can have adverse side effects and rarely result in resolution of pain. As such, there is a need for adjuvant analgesics that are non-addictive, have few adverse side effects and are effective for pain management across several chronic pain conditions. Oxytocin is a naturally occurring hormone that has gained attention for its potential analgesic properties. The objective of this trial is to evaluate the efficacy of intranasal oxytocin on pain and function among adults with chronic pain.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>This is a placebo-controlled, triple-blind, sequential, within-subject crossover trial. Adults with chronic neuropathic, pelvic and musculoskeletal pain will be recruited from three Canadian provinces (British Columbia, Alberta and Newfoundland and Labrador, respectively). Enrolled patients will provide one saliva sample pretreatment to evaluate basal oxytocin levels and polymorphisms of the oxytocin receptor gene before being randomised to one of two trial arms. Patients will self-administer three different oxytocin nasal sprays twice daily for a period of 2 weeks (ie, 24 IU, 48 IU and placebo). Patients will complete daily diaries, including standardised measures on day 1, day 7 and day 14. Primary outcomes include pain and pain-related interference. Secondary outcomes include emotional function, sleep disturbance and global impression of change. Intention-to-treat analyses will be performed to evaluate whether improvement in pain and physical function will be observed posttreatment.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>Trial protocols were approved by the Newfoundland and Labrador Health Research Ethics Board (HREB #20227), University of British Columbia Clinical Research Ethics Board (CREB #H20-00729), University of Calgary Conjoint Health Research Ethics Board (REB20 #0359) and Health Canada (Control # 252780). Results will be disseminated through publication in peer-reviewed journals and presentations at scientific conferences.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT04903002" ext-link-type="uri">NCT04903002</ext-link>; Pre-results.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>pain management</kwd>
                <kwd>clinical trials</kwd>
                <kwd>clinical pharmacology</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id>
                      <institution>Canadian Institutes of Health Research</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>426528</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>Strengths and limitations of this study</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>The effect of oxytocin will be evaluated across different chronic pain presentations (ie, musculoskeletal, pelvic and neuropathic pain), and clinically relevant outcomes will be measured as recommended by the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials.</p>
                </list-item>
                <list-item>
                  <p>Two doses of oxytocin will be administered, to evaluate a dose–response relationship.</p>
                </list-item>
                <list-item>
                  <p>The effect of oxytocin will only be evaluated over a 2-week period, precluding longer-term assessment.</p>
                </list-item>
                <list-item>
                  <p>The 48 IU dosing is the last course of treatment in both trial arms, which may introduce expectancy effects due to incomplete blinding at this dose.</p>
                </list-item>
                <list-item>
                  <p>Saliva samples will be collected to measure basal oxytocin levels and polymorphisms of the oxytocin receptor gene as potential moderators of treatment effect.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>In 2011, the Institute of Medicine concluded that chronic pain, defined as pain that persists longer than 3 months or beyond the expected duration of healing,<xref rid="R1" ref-type="bibr">1</xref> is a public health concern and should be treated as a disease itself.<xref rid="R2" ref-type="bibr">2</xref> Nationally representative data indicates that 20% of Canadians over 18 years of age<xref rid="R3" ref-type="bibr">3</xref> and 15% of children<xref rid="R4" ref-type="bibr">4</xref> suffer with chronic pain. The prevalence of chronic pain increases with age. Approximately 65% of community dwelling seniors and 80% of older adults living in care facilities experience chronic pain.<xref rid="R5" ref-type="bibr">5</xref></p>
              <p>Currently available treatments for chronic pain rarely result in complete resolution of symptoms,<xref rid="R6" ref-type="bibr">6</xref> and often do not produce concomitant improvements in physical and emotional functioning.<xref rid="R7" ref-type="bibr">7</xref> For example, a 2018 meta-analysis reported that 1 in 8 patients respond to opioid medication with a mean 6.9 mm (on a 100-mm Visual Analogue Scale) reduction in pain, small improvement in physical function and no improvement in mental function.<xref rid="R8" ref-type="bibr">8</xref> Moreover, current pharmacological treatments for pain, including opiates, are often addictive, associated with adverse effects,<xref rid="R9" ref-type="bibr">9 10</xref> and have limited effectiveness in areas such as neuropathic pain. Given the gap between suffering and adequate pain management, there is a need for analgesics that are safe, non-addictive, have low adverse effect profiles and offer effective relief for a variety of painful conditions.</p>
              <p>Intranasal oxytocin has gained increasing attention in recent years as a promising analgesic.<xref rid="R11" ref-type="bibr">11–14</xref> Oxytocin is a neuropeptide that is produced in the hypothalamus,<xref rid="R15" ref-type="bibr">15</xref> and released into the peripheral and central nervous system through independent pathways.<xref rid="R16" ref-type="bibr">16</xref> Evidence from several sources, including our team, suggests that oxytocin may be a safe and effective method for pain management.<xref rid="R12" ref-type="bibr">12 13</xref> Oxytocin may decrease pain sensitivity through three mechanisms<xref rid="R12" ref-type="bibr">12</xref>: (1) oxytocin is transported to an area involved in pain modulation, Laminae I, II and IV of the dorsal horn, through a hypothalamic–spinal projection.<xref rid="R16" ref-type="bibr">16</xref> Approximately 35% of neurons in the dorsal horn contain oxytocin receptors that act to inhibit pain-carrying Aδ-fibres and C-fibres<xref rid="R17" ref-type="bibr">17–19</xref>; (2) oxytocin binds to opioid receptors, and results in analgesic effects when administered to the periaqueductal grey, and effect that can be blocked with an opioid antagonist.<xref rid="R20" ref-type="bibr">20 21</xref> Furthermore, analgesic effects of endogenous and exogenous oxytocin can be blocked by the opioid antagonist naloxone<xref rid="R22" ref-type="bibr">22</xref>; and (3) oxytocin may decrease pain sensitivity by improving mood, reducing anxiety and buffering stress given that the induction of negative emotions are associated with heightened pain<xref rid="R23" ref-type="bibr">23–25</xref> and autonomic arousal.<xref rid="R24" ref-type="bibr">24</xref> In an informative controlled trial, intranasal administration of oxytocin in men resulted in greater calmness, less anxiety and a trend toward lower cortisol during the Trier Social Stress Test.<xref rid="R26" ref-type="bibr">26</xref></p>
              <p>Preliminary evidence suggests that oxytocin may be an effective adjuvant analgesic that is applicable to a broad patient population. Our team published a systematic review of the effect of oxytocin on pain in animals and humans.<xref rid="R12" ref-type="bibr">12</xref> Oxytocin had a reliable effect as defined by increasing pain tolerance in 29 out of 33 animal studies reviewed. This effect was large (standard mean difference=2.28), and persisted across central and peripheral modes of administration and various noxious stimuli (eg, heat, electric and chemical).<xref rid="R12" ref-type="bibr">12</xref> Results from research into the association between oxytocin and pain in humans have been variable due to methodological heterogeneity. For example, two studies have assessed associations between oxytocin and pain using experimental pain procedures in healthy adults, reporting a decrease in pain sensitivity to finger prick,<xref rid="R27" ref-type="bibr">27</xref> and no difference in pain unpleasantness to electric shock.<xref rid="R28" ref-type="bibr">28</xref> Interpreting these results is difficult due to methodological concerns, including insufficient sample size, one-dimensional pain measurement<xref rid="R28" ref-type="bibr">28</xref> and use of a poorly described finger prick pain procedure.<xref rid="R27" ref-type="bibr">27</xref> Our team conducted the first methodologically rigorous placebo-controlled, blinded, within-subjects crossover trial evaluating the effect of intranasal oxytocin on acute pain.<xref rid="R29" ref-type="bibr">29</xref> We observed clinically meaningful effects of oxytocin on pain, particularly neuropathic indicators. With regard to chronic pain, individuals experiencing chronic back pain,<xref rid="R30" ref-type="bibr">30</xref> headache,<xref rid="R31" ref-type="bibr">31</xref> constipation<xref rid="R32" ref-type="bibr">32</xref> and colon pain<xref rid="R33" ref-type="bibr">33</xref> have reported lower sensitivity to pain following the administration of oxytocin. Confidence in the association between oxytocin and chronic pain has been difficult to discern due to limitations in study designs, including selection of an insufficient control condition,<xref rid="R31" ref-type="bibr">31</xref> use of an intrathecal punch delivery method that likely confounded pain assessment,<xref rid="R30" ref-type="bibr">30</xref> administration of oxytocin peripherally without verification of influence in the central nervous system<xref rid="R33" ref-type="bibr">33</xref> or inadequate statistical power to detect meaningful effects.<xref rid="R32" ref-type="bibr">32 34</xref> Furthermore, no trial to date has assessed all clinically relevant outcomes endorsed by the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT)—an international group of experts that develop recommendations to improve the design, execution and interpretation of clinical trials of treatments for pain.<xref rid="R35" ref-type="bibr">35</xref></p>
              <p>Given the heterogeneity of extant trials, we propose a methodologically rigorous trial evaluating the efficacy of intranasal oxytocin on pain and function among men and women with chronic pain that evaluates clinically relevant outcomes endorsed by the IMMPACT.<xref rid="R35" ref-type="bibr">35</xref> Potential mediators and moderator of treatment effects will be assessed using basal oxytocin levels and polymorphisms of the oxytocin receptor gene measured using salivary assays given that: (1) chronic pain patients exhibit low basal oxytocin levels relative to controls,<xref rid="R30" ref-type="bibr">30 36 37</xref> and may reflect underlying abnormality in the oxytocinergic system<xref rid="R12" ref-type="bibr">12</xref> and (2) relative to those with an rs53576 A allele, individuals with a rs53576G/G oxytocin receptor genotype show reduced amygdala,<xref rid="R38" ref-type="bibr">38</xref> neuroendocrine<xref rid="R26" ref-type="bibr">26</xref> and stress reactivity across a range of contexts,<xref rid="R39" ref-type="bibr">39 40</xref> and report greater benefit from social support<xref rid="R41" ref-type="bibr">41</xref> following oxytocin administration. This represents a movement toward precision medicine.</p>
              <sec id="s1-1">
                <title>Research questions</title>
                <p>We will evaluate the efficacy of intranasal oxytocin when used as an adjuvant treatment (ie, in addition to usual therapies) for improving pain and function (physical and emotional) among men and women with chronic neuropathic, musculoskeletal or pelvic pain.</p>
              </sec>
              <sec id="s1-2">
                <title>Primary hypotheses</title>
                <p>Relative to placebo, patients will report greater improvement in: (1) pain intensity and (2) physical function measured using the Brief Pain Inventory–Short Form (BPI-SF) following a 2-week course of twice daily 24 IU or 48 IU intranasal oxytocin administration.</p>
              </sec>
              <sec id="s1-3">
                <title>Secondary hypotheses</title>
                <p>Patients will report improvement in emotional function, sleep and global impression of change following intranasal oxytocin administration relative to placebo.</p>
              </sec>
              <sec id="s1-4">
                <title>Exploratory questions</title>
                <p>Potential mediators and moderator of treatment effects will be assessed using basal oxytocin levels and polymorphisms of the oxytocin receptor gene measured using salivary assays. This represents a movement toward precision medicine.</p>
              </sec>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <sec id="s2-1">
                <title>Design and trial registration</title>
                <p>This is a multisite, placebo-controlled, triple-blind, sequential, within-subject crossover trial evaluating the efficacy of intranasal oxytocin on pain and function among patients with chronic pain. This is a basket trial consisting of heterogeneous populations of chronic pain conditions from multisites across Canada. This trial will be conducted in compliance with the trial protocol, good clinical practice, institutional ethics boards and applicable regulatory requirements, and is registered on ClinicalTrials.gov. A sample informed consent form can be located in the supplementary file: ‘OT and Pain – Consent MUN V1.2’.</p>
              </sec>
              <sec id="s2-2">
                <title>Study settings</title>
                <p>There is increasing recognition that most common chronic pain conditions are heterogeneous with a high degree of overlap and that most patients enrolled in clinical trials are not representative of community dwelling chronic pain patients.<xref rid="R42" ref-type="bibr">42</xref> As such, there will be four participating sites across three provinces, each province recruiting a different primary neuromusculoskeletal (NMSK) pain population. Adults with chronic neuropathic pain were recruited from the Jim Pattison Outpatient Care &amp; Surgical Centre Pain Clinic (JPOCSC-PC; Surrey) and the Initium Centre for Pain Management (ICPM; Abbotsford). The JPOCSC-PC is a multidisciplinary centre that accepts referrals from a catchment area of 2-million people. Two thousand patients are seen per month, of which approximately 20% present with chronic neuropathic pain. Consecutive women with chronic pelvic pain will be recruited from the Calgary Chronic Pain Centre (Calgary) and directly from the gynaecology clinics of MR and N-EM. The waitlist for an assessment of chronic pelvic pain is approximately 500 patients. Consecutive adults with chronic musculoskeletal pain will be recruited from the Carbonear General Hospital (Carbonear). Approximately, 40 patients with chronic pain are seen each week, of which approximately 60% present with primary shoulder, neck or back pain.</p>
              </sec>
              <sec id="s2-3">
                <title>Patient eligibility</title>
                <sec id="s2-3-1">
                  <title>Intersite inclusion criteria</title>
                  <p>(1) Adult (&gt;18 years) males and premenopausal women; (2) on stable medication for pain management for 3 months or more with no anticipated changes during 10 weeks of this trial; (3) moderate pain at baseline (ie, a score of 4–8 on a 10-point Numeric Rating Scale) to prevent floor and ceiling effects; and (4) can commit the use of two forms of effective contraception (eg, barrier methods), or one highly effective method, including abstinence, intrauterine device, intrauterine system, vasectomy, tubal ligation or hormonal contraceptive (eg, combined oral contraceptives, patch, vaginal ring, injectables and implants).</p>
                </sec>
                <sec id="s2-3-2">
                  <title>Intersite exclusion criteria</title>
                  <p>(1) Positive urine pregnancy test or contemplating pregnancy; (2) concurrent use of another nasal spray; (3) nasal pathology (eg, ears, nose and throat diagnosis); (4) diabetes insipidus; (5) current diagnosis or history of cancer; (6) significant unmanaged psychopathology (eg, severe depression as indicated by a score ≥15 on the Patient Health Questionnaire 9<xref rid="R43" ref-type="bibr">43</xref> due to its inverse association with patient adherence to procedures)<xref rid="R44" ref-type="bibr">44</xref>; (7) receiving hormone treatment for gender-related motivations; (8) documented cardiovascular event (eg, myocardial infarction); (9) known prolongation of the QTc interval; (10) known hypersensitivity to oxytocin; (11) known latex allergy or (12) known or suspected renal impairment. Exclusion criteria will be vetted through a review of patient medical records and self-report given the concordance between self-report and medical diagnosis.<xref rid="R45" ref-type="bibr">45</xref></p>
                </sec>
                <sec id="s2-3-3">
                  <title>Intra-site criteria</title>
                  <p>Men and women with primary neuropathic pain—pain arising as a direct consequence of a lesion or disease affecting the central or peripheral nervous system<xref rid="R46" ref-type="bibr">46</xref>—will be eligible. Neuropathic pain will be screened for using a score of 3+ on the Douleur Neuropathique 4 Interview,<xref rid="R47" ref-type="bibr">47</xref> and confirmed on clinical assessment.</p>
                  <sec id="s2-3-3-1">
                    <title>Calgary, AB</title>
                    <p>Women with chronic (intermittent or constant) pelvic musculoskeletal pain (ie, located primarily in the pelvic region and reproducible on palpation of the pelvic floor) who have not received a hysterectomy will be eligible. Women with a primary diagnosis of endometriosis, dysmenorrhoea, functional bowel disorder, interstitial cystitis, fibromyalgia or sacroiliac instability as defined by European Guidelines<xref rid="R48" ref-type="bibr">48</xref> will be excluded.</p>
                  </sec>
                  <sec id="s2-3-3-2">
                    <title>Carbonear, NL</title>
                    <p>Men and women with primary musculoskeletal pain of back, neck or shoulder origin will be eligible. Pain will be assessed using the BPI-SF and confirmed through physical examination.<xref rid="R49" ref-type="bibr">49 50</xref></p>
                  </sec>
                  <sec id="s2-3-3-3">
                    <title>Across sites</title>
                    <p>Adults with multiple chronic pain conditions will be eligible to participate so long as their primary pain complaint meets eligibility criteria. Recruiting different primary NMSK presentations will allow us to evaluate the generalisability of intranasal oxytocin across common chronic pain presentations typically observed within the community and may allow for improved optimisation of treatment in future work.</p>
                  </sec>
                </sec>
              </sec>
              <sec id="s2-4">
                <title>Procedure</title>
                <sec id="s2-4-1">
                  <title>Patient recruitment, screening and enrolment</title>
                  <p>Potentially eligible patients will be approached by a member of our study team during their regularly scheduled appointment at the clinic, and receive information about the objectives of the trial. Interested patients will undergo screening, including: (1) completion of a urine pregnancy test; (2) blood work to evaluate renal impairment (as defined by an eGFR &lt;45 by the Cockcroft-Gault equation), if the history suggests any stage or renal insufficiency, including history of diabetes, inflammatory diseases, hypertension and no creatinine has been drawn in the last 2 years; and (3) ECG to evaluate prolongation of the QTc interval among anyone who may be at risk, including those prescribed antidepressant medication. Patients who meet all eligibility criteria will be randomised to study arm before completing a baseline assessment. Recruitment will begin in September 2021 until the target sample size is recruited, or March 2024.</p>
                </sec>
                <sec id="s2-4-2">
                  <title>Randomisation, allocation and concealment</title>
                  <p>The commercially available software, <ext-link xlink:href="https://app.studyrandomizer.com/" ext-link-type="uri">https://app.studyrandomizer.com/,</ext-link> will be used to generate a list of randomly sequenced numbers for assigning patients to condition in a manner outlined in Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.<xref rid="R51" ref-type="bibr">51 52</xref> As depicted in <xref rid="F1" ref-type="fig">figure 1</xref>, patients will be randomised to one of two sequences: (1) 24 IU oxytocin, placebo and 48 IU oxytocin; or (2) placebo, 24 IU oxytocin and 48 IU oxytocin. Central randomisation stratified by province (British Columbia, Alberta and Newfoundland and Labrador) and performed using a 1:1 allocation schedule with permuted blocks of 4 and 6. Sex will be added as an additional stratification factor for sites in BC and NL. The lists will be uploaded on a web-based password protected randomisation system. When an eligible participant consents to the study, randomisation website will be contacted through a closed system and randomissation code will be assigned to the participant. Automated audit trails will document the patient allocation number and treatment sequence, and the date and time of transaction.</p>
                  <fig position="float" id="F1">
                    <label>Figure 1</label>
                    <caption>
                      <p>Flow chart of Randomized Controlled Trial design.</p>
                    </caption>
                    <graphic xlink:href="bmjopen-2021-055039f01" position="float"/>
                  </fig>
                </sec>
                <sec id="s2-4-3">
                  <title>Blinding</title>
                  <p>This is a triple-blind study. In order to protect against expectation effects and biases, neither site investigators nor patients will know which nasal spray contains oxytocin or which sequence of conditions patients are assigned. The allocation sequence will be concealed from researchers using automated randomisation. The bottles containing 24 IU oxytocin, 48 IU oxytocin and placebo will be identical in appearance, smell, texture and taste, and only identifiable through a colour labelling system known to the site pharmacists and study sponsor. Each province’s randomisation sequence will be accessed by the site pharmacist and bottles prepared accordingly. Neither the Research Assistant assessing outcomes nor the statistician performing analyses will be unaware of condition. Patient blinding can be broken in the case of an adverse event (eg, emergency department attendance). Patients will be provided a study card with a number to call to reach the central administrator who can de-identify condition in the unlikely case of an adverse drug reaction. The decision to unmask will be made on a case-by-case basis and will depend on potential risk.</p>
                </sec>
                <sec id="s2-4-4">
                  <title>Baseline assessment</title>
                  <p>Baseline assessments will involve: (1) completion of study measures, refer to <xref rid="T1" ref-type="table">table 1</xref>; (2) collection of approximately 4 mL of saliva into cryovials using a standard unstimulated passive drool technique. Saliva samples will be frozen until shipped to Salimetrics for analysis of salivary oxytocin concentration and genetic polymorphism in the oxytocin receptor gene OXTR rs53576; and (3) training on procedures for nasal spray administration. Patients will be provided with the option of completing baseline assessments immediately following randomisation, or scheduling a convenient time within 2 weeks. Baseline assessments for women will be scheduled to occur within close proximity to the start of the luteal phase of the menstrual cycle (ie, days 14–28) as this is the stage during which women report greatest pain.<xref rid="R53" ref-type="bibr">53</xref> Due to the impact of the global pandemic, patients will have the option of completing study measures virtually. Patients will attend clinic to provide a saliva sample, undergo nasal spray training and receive their assigned nasal spray. Clinic attendance will be scheduled in the afternoon to avoid diurnal fluctuation in saliva oxytocin. Patients will be asked to avoid foods with high sugar, acidity or caffeine 1 hour prior to visiting the clinic as these can confound saliva assays.</p>
                  <table-wrap position="float" id="T1">
                    <label>Table 1</label>
                    <caption>
                      <p>Schedule of assessments</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                          <td align="left" valign="bottom" rowspan="1" colspan="6">Randomisation</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="2" colspan="1"> <break/> Testing variables</td>
                          <td align="left" valign="bottom" rowspan="2" colspan="1"> <break/> Phone screen</td>
                          <td align="left" valign="bottom" rowspan="2" colspan="1"> <break/> Baseline</td>
                          <td align="left" valign="bottom" rowspan="1" colspan="3">2-week diaries</td>
                          <td align="left" valign="bottom" rowspan="2" colspan="1"> <break/> Follow-up</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Daily diary</td>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Day 7 of diary</td>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Day 14 of diary</td>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Inclusion criteria</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Sociodemographics</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Medical history</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Vitals</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Pain NRS</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> BPI-SF intensity</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> BPI-SF interference</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Emotional function</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> Mood</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> DASS</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Sleep</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Global impression of change</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Expectancy</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Side effects</td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">X</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="T1_FN1">
                        <p>BPI-SF, Brief Pain Inventory–Short Form; DASS, Depression, Anxiety and Stress Scale; NRS, Numeric Rating Scale.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="s2-4-5">
                  <title>Trial interventions</title>
                  <p>The intervention will span three 2-week conditions (24 IU, 48 IU and placebo) and two 2-week wash-out periods for a total duration of 10 weeks.</p>
                  <sec id="s2-4-5-1">
                    <title>Experimental condition</title>
                    <p>There will be two experimental conditions. Experimental condition 1: patients will self-administer a 2-week course of 24 IU intranasal oxytocin (4 IU per puff (12 IU delivered to each nostril); syntocinon, Novartis, Switzerland), twice daily (once in the morning and once in the evening). Experimental condition 2: patients will self-administer a 2-week course of 48 IU intranasal oxytocin (4 IU per puff (24 IU delivered to each nostril)), twice daily. Given that treatment adherence is crucial to treatment success, we will ensure standardisation of nasal spray administration by training patients in the self-administration of intranasal oxytocin in accordance with published recommendations.<xref rid="R54" ref-type="bibr">54</xref> Intranasal administration of oxytocin is an effective method of administering the neuropeptide across the blood brain barrier.<xref rid="R55" ref-type="bibr">55</xref> Twice daily dosing will ensure elevated central concentration of oxytocin throughout the day given that salivary concentration of oxytocin remains elevated for 7 hours following intranasal administration.<xref rid="R56" ref-type="bibr">56</xref> Patients will be instructed to store nasal spray at room temperature (between 15°C and 25°C) after first use. The inclusion of two doses will allow us to determine the lowest effective dose (ie, 24 IU or 48 IU), which will inform future trials assessing long-term treatment optimisation. Doses of 24 IU and 48 IU were chosen because these are the most frequently used doses in studies with humans and have proven safe for long-term study.<xref rid="R49" ref-type="bibr">49 50</xref></p>
                  </sec>
                  <sec id="s2-4-5-2">
                    <title>Control condition</title>
                    <p>Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in the experimental condition.</p>
                  </sec>
                  <sec id="s2-4-5-3">
                    <title>Wash-out periods</title>
                    <p>Conditions will be separated by a wash-out period of approximately 2 weeks to ensure that oxytocin has fully cleared the system. This time frame is sufficient given that the half-life of oxytocin administered centrally using nasal spray is 2–7 hours and 7 half-lives will be achieved for clearance in 14–49 hours. A 2-week wash-out will also allow each course of intranasal administration to coincide with the same phase of womens’ menstrual cycle (ie, the luteal phase). This is relevant given that oestrogen has a priming effect on oxytocin synthesis, release and receptor expression.<xref rid="R57" ref-type="bibr">57</xref></p>
                  </sec>
                </sec>
                <sec id="s2-4-6">
                  <title>Follow-Up</title>
                  <p>Patients will be contacted over the phone 2 weeks following completion of the trial (12 weeks following randomisation) to assess for potential adverse events.</p>
                </sec>
              </sec>
              <sec id="s2-5">
                <title>Patient and public involvement</title>
                <p>Patients with lived experience were consulted in the design of this project and assisted in preparation of study materials. Engagement will continue throughout trial conduction and be emphasised when preparing materials for dissemination.</p>
              </sec>
              <sec id="s2-6">
                <title>Measures</title>
                <p>Refer to <xref rid="T1" ref-type="table">table 1</xref> for schedule of assessments.</p>
                <sec id="s2-6-1">
                  <title>Primary outcome</title>
                  <p>The primary outcomes will be the between condition (24 IU vs placebo; 48 IU vs placebo) change in pain intensity and physical function from day 1 to day 14 measured using the BPI-SF.<xref rid="R58" ref-type="bibr">58</xref> The BPI-SF measures pain intensity, the impact of pain on seven daily activities (eg, activity, work and sleep) and analgesic use. It has been recommended for use in trials measuring pain across multiple chronic pain conditions.<xref rid="R35" ref-type="bibr">35</xref> The BPI-SF was originally designed to measure cancer pain but has been shown to be a reliable and valid instrument for measuring non-cancer pain.<xref rid="R59" ref-type="bibr">59–62</xref> Two week and 1-month test–retest values for pain and function typically range between 0.72 and 0.98.<xref rid="R63" ref-type="bibr">63</xref></p>
                </sec>
                <sec id="s2-6-2">
                  <title>Secondary outcomes</title>
                  <p>Secondary outcomes include emotional function, sleep disturbance and global impression of change. Emotional function will be measured weekly using the 21-item Depression, Anxiety and Stress Scale.<xref rid="R64" ref-type="bibr">64</xref> Scales for depression, anxiety and stress are considered to approximate facets of diagnostic categories, including Depression scale for mood disorders, Anxiety scale for panic disorder and Stress scale for generalised anxiety disorder.<xref rid="R65" ref-type="bibr">65</xref> Sleep disturbance will be assessed weekly with the Medical Outcomes Study Sleep Scale (MOS-S).<xref rid="R66" ref-type="bibr">66</xref> The MOS-S is a 12-item self-report measure designed to assess the important dimensions of sleep, including initiation, maintenance, respiratory problems, quantity, quality and somnolence. Global change across the course of study will be measured at the end of each 2-week course of nasal spray using the Patients<italic toggle="yes">’</italic> Global Impression of Change (PGIC) Scale.<xref rid="R67" ref-type="bibr">67</xref> There has been a wide use of the PGIC Scale in chronic pain trials,<xref rid="R68" ref-type="bibr">68 69</xref> and data provide a responsive and readily interpretable measure of participants’ assessment of clinical importance of treatment.</p>
                </sec>
                <sec id="s2-6-3">
                  <title>Daily diaries</title>
                  <p>Ambulatory assessments will be administered by way of REDCap. Patients will complete electronic diaries throughout each 2-week course of nasal spray administration. Patients will make daily recording of: (1) time of nasal spray administration; (2) average pain using a 0 ‘no pain’ to 10 ‘pain as bad as you can imagine’ scale; (3) the degree to which pain has interfered with enjoyment in life and general activity using scales with anchors at 0 ‘does not interfere’ and 10 ‘interferes completely’. Validated measures will be completed during day 1, day 7 and day 14, refer to <xref rid="T1" ref-type="table">table 1</xref>. Patients will be asked to guess whether the nasal spray administered contained oxytocin or placebo following each 14-day course of nasal spray administration.</p>
                </sec>
                <sec id="s2-6-4">
                  <title>Demographics and covariates</title>
                  <p>A demographic questionnaire will collect age, ethnicity, medical comorbidities, medications taken, employment status, marital status, obstetrical history, menstrual history, urinary symptoms, headaches, substance use and smoking status. Concern over pain will be assessed using the 13-item Pain Catastrophizing Scale.<xref rid="R70" ref-type="bibr">70</xref> Treatment expectations will be measured with the Credibility/Expectancy Questionnaire.<xref rid="R71" ref-type="bibr">71</xref> Allodynia/hyperalgesia will be assessed using the Central Sensitisation Inventory<xref rid="R72" ref-type="bibr">72 73</xref> and confirmed with Q-tip testing.<xref rid="R74" ref-type="bibr">74</xref></p>
                </sec>
                <sec id="s2-6-5">
                  <title>Side effects and safety monitoring</title>
                  <p>As recommended for trials of chronic pain,<xref rid="R75" ref-type="bibr">75</xref> side effects will be assessed using open-ended prompts (ie, have you experienced any unwanted symptoms in the past 24 hours?) and the Symptom Assessment Schedule<xref rid="R76" ref-type="bibr">76</xref> supplemented with additional symptoms (eg, euphoria, nasal irritation and dizziness) identified in a recent trial evaluating the effect of intranasal oxytocin on pain in a sample of 14 women with fibromyalgia.<xref rid="R34" ref-type="bibr">34</xref></p>
                </sec>
              </sec>
              <sec id="s2-7">
                <title>Sample size calculation</title>
                <p>We based our sample size calculation on the number of patients needed to evaluate a clinically significant reduction in pain intensity and improvement in physical function of the primary outcomes: change in pain intensity and physical function from day 1 to day 14 that occurs between conditions (24 IU oxytocin vs placebo; 48 IU oxytocin vs placebo). The hypothesis tests are one sided and the trial is powered using a sequential, repeated-measures crossover design with one interim analysis to monitor the preliminary activity of the 24 IU and 48 IU doses of oxytocin relative to placebo (refer to section 3.2.1 for greater detail on the interim analysis).</p>
                <p>The overall type I error rate will be 0.05 and the O’Brien and Fleming’s method<xref rid="R77" ref-type="bibr">77</xref> will be used to control for the inflation of type I error due to the interim analysis. The interim analysis will be conducted when primary outcomes are available for half of the proposed sample. The Sidak method<xref rid="R78" ref-type="bibr">78</xref> will be used to adjust for multiple comparisons (ie, α=0.0127 after adjusting for 4 comparisons: 24 IU and 48 IU doses of oxytocin compared with placebo for pain intensity and physical function). Based on previous research with chronic pain populations,<xref rid="R58" ref-type="bibr">58</xref> we assume a SD of 2.0 for pain intensity and physical function and a block-based symmetric correlation matrix under which the 2-week correlation within the same arm is assumed to be 0.8<xref rid="R63" ref-type="bibr">63</xref>; the subcorrelation matrix of day 1 and day 14 pain intensity and physical function across two arms is comparable for any two arms; and the correlation of day 1 and day 1 on two arms equals that of day 14 and day 14. We anticipate that the correlation of day 1 and day 14 cross-arms will be lower than the correlation of the same day pain intensity/physical function. As a conservative measure, we assume the correlation of day 1 and day 14 is comparable to the same day correlation cross two arms and a better power will be achieved if the correlation between day 1 and day 14 is lower. The sample size is determined as the largest for two scenarios on whether the subcorrelation matrix of day 1 and day 14 is stable over phases or not.</p>
                <p>For the scenario of stable subcorrelation matrix of day 1 and day 14, all phases data will be included in the analysis. Target power is 0.9 to detect a 0.5 SD difference in pain intensity/physical function, which corresponds to an effect size of 0.56 for the outcomes of change between day 1 and day 14 under the aforementioned assumptions on the covariance matrix. The required sample size is 41 per province to accommodate one interim analysis. If the subcorrelation matrix of day 1 and day 14 is unstable cross phases, only the first two phases data will be included in the analysis and the size for evaluating the efficacy of the 24 IU and 48 IU over the placebo is reduced to 2/3, where the two samples are independent (α=0.0127 using Sidak). Under this scenario, the power is set as 0.8 for the same effect size and the required sample size is 54, which is increased to 81 accounting for abandoning the phase III data due to instability of the correlation. Therefore, the sample size of 81 per province will be used and this is the robust size to guarantee at least 80% power and an overall type I error of 0.05 with an interim analysis for different scenarios of the correlation matrix of pain intensity/physical function. The covariates of sex and province will be adjusted and the rule of 8 additional cases per covariate will be followed for the combined analysis on the efficacy of 24 IU and 48 IU oxytocin relative to placebo. Accounting for a potential attrition rate of 20% and the balance among the 2 sequences per province, a total sample of 336 patients (112 per province) is required.</p>
              </sec>
              <sec id="s2-8">
                <title>Data analysis</title>
                <p>An intention-to-treat (ITT) analysis will be performed,<xref rid="R79" ref-type="bibr">79</xref> in accordance with recommendations by CONSORT.<xref rid="R51" ref-type="bibr">51 52</xref> ITT analyses provide an assessment of the practical impact of the treatment. Primary analyses: the hypotheses that improvement in pain and physical function will be observed following 2-week administration of oxytocin nasal spray relative to placebo will be assessed using BPI-SF average 24-hour pain intensity scores. Using linear mixed models in SAS, the analytic strategy will be a mixed models analysis of covariance with fixed effects (time (day 1 and day 14) and condition (24 IU oxytocin, 48 IU oxytocin and placebo)) and random effect (individual), and sex (male and female) as between-subject factor after adjusting for relevant covariates (ie, province, basal oxytocin at baseline, expectation, pain catastrophising and medical comorbidity). One interim analysis will be performed (see 2.17 for details). Based on previous literature, BPI-SF assessed pain is a relatively ‘well-behaved’ variable with respect to the assumptions of a general linear model.<xref rid="R80" ref-type="bibr">80</xref> Even so, prior to conducting any analyses, preliminary examination of the assumptions of the General Linear Model will be conducted.<xref rid="R80" ref-type="bibr">80</xref> Should the data indicate violation of assumption, we will perform appropriate transformations and/or consider the appropriate interaction term(s).<xref rid="R80" ref-type="bibr">80</xref> Missing data will be handled using multiple imputation<xref rid="R81" ref-type="bibr">81</xref> in accordance to Harrell’s guidelines.<xref rid="R82" ref-type="bibr">82</xref> Secondary analyses: the effects of the intervention on change in emotional function, sleep disturbance and global impression of change between conditions will be evaluated in a manner analogous to that described above. Exploratory analyses will be performed to evaluate whether basal oxytocin concentration or polymorphism of the oxytocin gene receptor moderate or mediate treatment outcomes.</p>
                <sec id="s2-8-1">
                  <title>Frequency of analysis</title>
                  <p>An interim analysis will be conducted when complete data are available from half of the desired sample size. The interim analysis will be used to decide: (1) stop the trial for efficacy if overwhelming evidence indicates that the 48 IU dose of intranasal oxytocin is efficacious relative to placebo (p value &lt;0.0083); (2) drop the 24 IU dose for inefficacy if evidence supports a conservative test of the null hypothesis that 24 IU oxytocin is equivalent to placebo if the conditional power is less than 0.2 if continuing the stage 2 data collection; or (3) continue the trial as planned. The O’Brien and Fleming’s method will control the overall type I rate at 0.0127 with 0.0083 α spending at the interim, and the overall type II error rate at 0.1 with 0.029 spending at the interim for each of the 24 IU and 48 IU doses and primary outcome. Final analyses will commence after the follow-up has been completed for the final participant enrolled (eg, May 2024) and span 3 months in duration.</p>
                </sec>
                <sec id="s2-8-2">
                  <title>Subgroup analyses</title>
                  <p>Subgroup analyses (eg, dose of oxytocin, province and sex) are built into the analytic plan. Secondary analyses include interactions between dose, pain type, sex and gender.</p>
                </sec>
              </sec>
              <sec id="s2-9">
                <title>Risk management and safety monitoring board</title>
                <p>A Data and Safety Monitoring Board (DSMB) has been established to perform (unblinded) analyses according to the DSMB charter. The DSMB is composed of three independent clinical experts, and a statistician with expertise in Randomized Controlled Trials. The DSMB will advise on any serious adverse event reported during the conduct of the trial. Moreover, safety and efficacy will be evaluated during the interim analysis. Early termination will only occur if the DSMB is unanimous in their conclusion of an unfavourable benefit-to-risk ratio.<xref rid="R83" ref-type="bibr">83</xref> Strict termination criteria were not established a priori given that: (1) rescue medication is not needed for intranasal oxytocin. The best method to resolve side effects is to discontinue use of the drug, which is our recommended course of action; (2) chronic NMSK pain is not a life-threatening condition; (3) study duration is brief; and (4) intranasal oxytocin has been extensively studied and side effects are rare and benign.<xref rid="R84" ref-type="bibr">84</xref> The advice of the DSMB will be sent to the study sponsor. Should the sponsor decide not to fully implement the advice of the DSMB, the sponsor will send the advice to the reviewing medical research ethics committee, including a note to substantiate why (part of) the advice of the DSMB will not be followed.</p>
              </sec>
              <sec id="s2-10">
                <title>Ethics and dissemination</title>
                <p>Results from this feasibility trial will be disseminated to the academic community through conference presentations and the publication of peer-reviewed manuscripts. Results will be posted to our website <ext-link xlink:href="www.munbehaviourmedicine.ca" ext-link-type="uri">www.munbehaviourmedicine.ca</ext-link> and made available to patients, providers and the general public. Trial protocols were approved by the Newfoundland and Labrador Health Research Ethics Board (HREB #20227), University of Calgary Conjoint Health Research Ethics Board (REB20 #0359), University of British Columbia Clinical Research Ethics Board (CREB #H20-00729) and Health Canada (Control # 252780).</p>
              </sec>
              <sec id="s2-11">
                <title>Data management</title>
                <p>Data will be collected, de-identified and stored. Electronic data will be stored on password-protected servers in encrypted files. De-identified data will be retained for 25 years and made available to members of the investigative team. Individual participant de-identified data (including data dictionaries) will be made available beginning 3 months after final follow-up data has been collected (anticipated September 2024) to researchers who provide a methodologically sound proposal for the purpose of achieving the aims of the approved proposal. Data sharing will be enacted with a data-transfer agreement between the sending and receiving institutions. Proposals should be directed to the corresponding author (JR).</p>
              </sec>
              <sec id="s2-12">
                <title>Patient adherence</title>
                <p>We will use a multi-pronged approach to encourage patient engagement. First, the timeline and demands of the trial will be explicitly discussed at the outset with patients, who will be asked to sign a behavioural contract to commit to trying to meet the requirements. Second, patients will receive telephone reminders prior to each laboratory visit and again if they miss one visit. Third, expectations will be developed for attendance. Patients will know our research staff by name and made aware that their research associate has an appointment scheduled with them and will be awaiting their arrival. Fourth, patients who have difficulties attending sessions will be provided with a motivational conversation during which ambivalence towards attending sessions will be openly discussed with the goal of securing commitment to attend sessions. We have successfully employed these strategies with some very challenging patient groups (eg, patients with cancer-related fatigue and obese patients attending exercise sessions). These strategies have been identified by Cochrane reviews as methods for improving patient recruitment<xref rid="R85" ref-type="bibr">85</xref> and retention.<xref rid="R86" ref-type="bibr">86</xref></p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2021-055039.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="bmjopen-2021-055039supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e288">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2021-055039.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e289">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2021-055039.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> All authors (JR, TC, LC, DF, AM, AAM, N-EM, PP, MR and YY) were involved in the conceptualisation and design of the trial, made significant intellectual contributions to the written protocol and have approved the submitted version.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This work was supported by the Canadian Institutes of Health Research (grant number: 426528). The funder was not involved in trial design, conduct or reporting.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; peer reviewed for ethical and funding approval prior to submission.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data sharing not applicable as no datasets generated and/or analysed for this study. Individual participant de-identified data (including data dictionaries) will be made available beginning 3-months after final follow-up data has been collected (anticipated September 2024) to researchers who provide a methodologically sound proposal for the purpose of achieving the aims of the approved proposal. Data sharing will be enacted with a data-transfer agreement between the sending and receiving institutions. Proposals should be directed to Joshua Rash (jarash@mun.ca)</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Merskey</surname><given-names>H</given-names></string-name></person-group>. <article-title>Pain terms: a list with definitions and notes on usage. Recommended by the International association for the study of pain</article-title>. <source>Pain</source><year>1979</year>;<volume>6</volume>:<fpage>249</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">460932</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>IoM</surname><given-names>IOM</given-names></string-name></person-group>. <source>Relieving pain in America: a blueprint for transforming prevention, care, education, and research</source>. <publisher-loc>Washington DC</publisher-loc>: <publisher-name>National Academy of Sciences</publisher-name>, <year>2011</year>.</mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schopflocher</surname><given-names>D</given-names></string-name>, <string-name><surname>Taenzer</surname><given-names>P</given-names></string-name>, <string-name><surname>Jovey</surname><given-names>R</given-names></string-name></person-group>. <article-title>The prevalence of chronic pain in Canada</article-title>. <source>Pain Res Manag</source><year>2011</year>;<volume>16</volume>:<fpage>445</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1155/2011/876306</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22184555?><pub-id pub-id-type="pmid">22184555</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stanford</surname><given-names>EA</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>CT</given-names></string-name>, <string-name><surname>Biesanz</surname><given-names>JC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The frequency, trajectories and predictors of adolescent recurrent pain: a population-based approach</article-title>. <source>Pain</source><year>2008</year>;<volume>138</volume>:<fpage>11</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2007.10.032</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18093737?><pub-id pub-id-type="pmid">18093737</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hadjistavropoulos</surname><given-names>T</given-names></string-name>, <string-name><surname>Marchildon</surname><given-names>GP</given-names></string-name>, <string-name><surname>Fine</surname><given-names>PG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Transforming long-term care pain management in North America: the policy-clinical interface</article-title>. <source>Pain Med</source><year>2009</year>;<volume>10</volume>:<fpage>506</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4637.2009.00566.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19254336?><pub-id pub-id-type="pmid">19254336</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turk</surname><given-names>DC</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>HD</given-names></string-name>, <string-name><surname>Cahana</surname><given-names>A</given-names></string-name></person-group>. <article-title>Treatment of chronic non-cancer pain</article-title>. <source>Lancet</source><year>2011</year>;<volume>377</volume>:<fpage>2226</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60402-9</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21704872?><pub-id pub-id-type="pmid">21704872</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martin</surname><given-names>BI</given-names></string-name>, <string-name><surname>Deyo</surname><given-names>RA</given-names></string-name>, <string-name><surname>Mirza</surname><given-names>SK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Expenditures and health status among adults with back and neck problems</article-title>. <source>JAMA</source><year>2008</year>;<volume>299</volume>:<fpage>656</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1001/jama.299.6.656</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18270354?><pub-id pub-id-type="pmid">18270354</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Busse</surname><given-names>JW</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Kamaleldin</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opioids for chronic noncancer pain: a systematic review and meta-analysis</article-title>. <source>JAMA</source><year>2018</year>;<volume>320</volume>:<fpage>2448</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2018.18472</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30561481?><pub-id pub-id-type="pmid">30561481</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gregorian</surname><given-names>RS</given-names></string-name>, <string-name><surname>Gasik</surname><given-names>A</given-names></string-name>, <string-name><surname>Kwong</surname><given-names>WJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians</article-title>. <source>J Pain</source><year>2010</year>;<volume>11</volume>:<fpage>1095</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2010.02.007</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20452835?><pub-id pub-id-type="pmid">20452835</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sostres</surname><given-names>C</given-names></string-name>, <string-name><surname>Gargallo</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Arroyo</surname><given-names>MT</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract</article-title>. <source>Best Pract Res Clin Gastroenterol</source><year>2010</year>;<volume>24</volume>:<fpage>121</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpg.2009.11.005</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20227026?><pub-id pub-id-type="pmid">20227026</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>González-Hernández</surname><given-names>A</given-names></string-name>, <string-name><surname>Rojas-Piloni</surname><given-names>G</given-names></string-name>, <string-name><surname>Condés-Lara</surname><given-names>M</given-names></string-name></person-group>. <article-title>Oxytocin and analgesia: future trends</article-title>. <source>Trends Pharmacol Sci</source><year>2014</year>;<volume>35</volume>:<fpage>549</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2014.09.004</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/25270768?><pub-id pub-id-type="pmid">25270768</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rash</surname><given-names>JA</given-names></string-name>, <string-name><surname>Aguirre-Camacho</surname><given-names>A</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>TS</given-names></string-name></person-group>. <article-title>Oxytocin and pain: a systematic review and synthesis of findings</article-title>. <source>Clin J Pain</source><year>2014</year>;<volume>30</volume>:<fpage>453</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1097/AJP.0b013e31829f57df</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23887343?><pub-id pub-id-type="pmid">23887343</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tracy</surname><given-names>LM</given-names></string-name>, <string-name><surname>Georgiou-Karistianis</surname><given-names>N</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>SJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin and the modulation of pain experience: implications for chronic pain management</article-title>. <source>Neurosci Biobehav Rev</source><year>2015</year>;<volume>55</volume>:<fpage>53</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.04.013</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/25956252?><pub-id pub-id-type="pmid">25956252</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rash</surname><given-names>JA</given-names></string-name>, <string-name><surname>Toivonen</surname><given-names>K</given-names></string-name>, <string-name><surname>Robert</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Protocol for a placebo-controlled, within-participants crossover trial evaluating the efficacy of intranasal oxytocin to improve pain and function among women with chronic pelvic musculoskeletal pain</article-title>. <source>BMJ Open</source><year>2017</year>;<volume>7</volume>:<elocation-id>e014909</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2016-014909</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28416501?></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Viero</surname><given-names>C</given-names></string-name>, <string-name><surname>Shibuya</surname><given-names>I</given-names></string-name>, <string-name><surname>Kitamura</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Review: oxytocin: crossing the bridge between basic science and pharmacotherapy</article-title>. <source>CNS Neurosci Ther</source><year>2010</year>;<volume>16</volume>:<fpage>e138</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00185.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20626426?><pub-id pub-id-type="pmid">20626426</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gimpl</surname><given-names>G</given-names></string-name>, <string-name><surname>Fahrenholz</surname><given-names>F</given-names></string-name></person-group>. <article-title>The oxytocin receptor system: structure, function, and regulation</article-title>. <source>Physiol Rev</source><year>2001</year>;<volume>81</volume>:<fpage>629</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.2001.81.2.629</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11274341?><pub-id pub-id-type="pmid">11274341</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Breton</surname><given-names>J-D</given-names></string-name>, <string-name><surname>Veinante</surname><given-names>P</given-names></string-name>, <string-name><surname>Uhl-Bronner</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition</article-title>. <source>Mol Pain</source><year>2008</year>;<volume>4</volume>:<elocation-id>19</elocation-id>. <pub-id pub-id-type="doi">10.1186/1744-8069-4-19</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18510735?><pub-id pub-id-type="pmid">18510735</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Condés-Lara</surname><given-names>M</given-names></string-name>, <string-name><surname>Rojas-Piloni</surname><given-names>G</given-names></string-name>, <string-name><surname>Martínez-Lorenzana</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Hypothalamospinal oxytocinergic antinociception is mediated by GABAergic and opiate neurons that reduce A-delta and C fiber primary afferent excitation of spinal cord cells</article-title>. <source>Brain Res</source><year>2009</year>;<volume>1247</volume>:<fpage>38</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2008.10.030</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18996098?><pub-id pub-id-type="pmid">18996098</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jo</surname><given-names>YH</given-names></string-name>, <string-name><surname>Stoeckel</surname><given-names>ME</given-names></string-name>, <string-name><surname>Freund-Mercier</surname><given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin modulates glutamatergic synaptic transmission between cultured neonatal spinal cord dorsal horn neurons</article-title>. <source>J Neurosci</source><year>1998</year>;<volume>18</volume>:<fpage>2377</fpage>–<lpage>86</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/9502799?><pub-id pub-id-type="pmid">9502799</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ge</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lundeberg</surname><given-names>T</given-names></string-name>, <string-name><surname>Yu</surname><given-names>L-C</given-names></string-name></person-group>. <article-title>Blockade effect of mu and kappa opioid antagonists on the anti-nociception induced by intra-periaqueductal grey injection of oxytocin in rats</article-title>. <source>Brain Res</source><year>2002</year>;<volume>927</volume>:<fpage>204</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(01)03346-7</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11821014?><pub-id pub-id-type="pmid">11821014</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Liang</surname><given-names>J-Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides</article-title>. <source>Peptides</source><year>2011</year>;<volume>32</volume>:<fpage>1255</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2011.03.007</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21439337?><pub-id pub-id-type="pmid">21439337</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miranda-Cardenas</surname><given-names>Y</given-names></string-name>, <string-name><surname>Rojas-Piloni</surname><given-names>G</given-names></string-name>, <string-name><surname>Martínez-Lorenzana</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist</article-title>. <source>Pain</source><year>2006</year>;<volume>122</volume>:<fpage>182</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2006.01.029</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16527400?><pub-id pub-id-type="pmid">16527400</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berna</surname><given-names>C</given-names></string-name>, <string-name><surname>Leknes</surname><given-names>S</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>EA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Induction of depressed mood disrupts emotion regulation neurocircuitry and enhances pain unpleasantness</article-title>. <source>Biol Psychiatry</source><year>2010</year>;<volume>67</volume>:<fpage>1083</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.01.014</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20303069?><pub-id pub-id-type="pmid">20303069</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rainville</surname><given-names>P</given-names></string-name>, <string-name><surname>Bao</surname><given-names>QVH</given-names></string-name>, <string-name><surname>Chrétien</surname><given-names>P</given-names></string-name></person-group>. <article-title>Pain-related emotions modulate experimental pain perception and autonomic responses</article-title>. <source>Pain</source><year>2005</year>;<volume>118</volume>:<fpage>306</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2005.08.022</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16289802?><pub-id pub-id-type="pmid">16289802</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rhudy</surname><given-names>JL</given-names></string-name>, <string-name><surname>Meagher</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Fear and anxiety: divergent effects on human pain thresholds</article-title>. <source>Pain</source><year>2000</year>;<volume>84</volume>:<fpage>65</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3959(99)00183-9</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/10601674?><pub-id pub-id-type="pmid">10601674</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heinrichs</surname><given-names>M</given-names></string-name>, <string-name><surname>Baumgartner</surname><given-names>T</given-names></string-name>, <string-name><surname>Kirschbaum</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress</article-title>. <source>Biol Psychiatry</source><year>2003</year>;<volume>54</volume>:<fpage>1389</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-3223(03)00465-7</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/14675803?><pub-id pub-id-type="pmid">14675803</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uryvaev</surname><given-names>YV</given-names></string-name>, <string-name><surname>Petrov</surname><given-names>G</given-names></string-name></person-group>. <article-title>Extremely low doses of oxytocin reduce pain sensitivity in men</article-title>. <source>Bull Exp Biol Med</source><year>1996</year>;<volume>122</volume>:<fpage>1071</fpage>–<lpage>3</lpage>.</mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singer</surname><given-names>T</given-names></string-name>, <string-name><surname>Snozzi</surname><given-names>R</given-names></string-name>, <string-name><surname>Bird</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of oxytocin and prosocial behavior on brain responses to direct and vicariously experienced pain</article-title>. <source>Emotion</source><year>2008</year>;<volume>8</volume>:<elocation-id>781</elocation-id>. <pub-id pub-id-type="doi">10.1037/a0014195</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19102589?><pub-id pub-id-type="pmid">19102589</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rash</surname><given-names>JA</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>TS</given-names></string-name></person-group>. <article-title>The effect of intranasal oxytocin administration on acute cold pressor pain: a placebo-controlled, double-blind, within-participants crossover investigation</article-title>. <source>Psychosom Med</source><year>2014</year>;<volume>76</volume>:<fpage>422</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/PSY.0000000000000068</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24979580?><pub-id pub-id-type="pmid">24979580</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J</given-names></string-name></person-group>. <article-title>Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system</article-title>. <source>Spine</source><year>1994</year>;<volume>19</volume>:<fpage>867</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1097/00007632-199404150-00001</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/8009342?><pub-id pub-id-type="pmid">8009342</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y-L</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The interaction between the oxytocin and pain modulation in headache patients</article-title>. <source>Neuropeptides</source><year>2013</year>;<volume>47</volume>:<fpage>93</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.npep.2012.12.003</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23375440?><pub-id pub-id-type="pmid">23375440</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ohlsson</surname><given-names>B</given-names></string-name>, <string-name><surname>Truedsson</surname><given-names>M</given-names></string-name>, <string-name><surname>Bengtsson</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of long-term treatment with oxytocin in chronic constipation; a double blind, placebo-controlled pilot trial</article-title>. <source>Neurogastroenterol Motil</source><year>2005</year>;<volume>17</volume>:<fpage>697</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2982.2005.00679.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16185308?><pub-id pub-id-type="pmid">16185308</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Louvel</surname><given-names>D</given-names></string-name>, <string-name><surname>Delvaux</surname><given-names>M</given-names></string-name>, <string-name><surname>Felez</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome</article-title>. <source>Gut</source><year>1996</year>;<volume>39</volume>:<fpage>741</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/gut.39.5.741</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/9014776?><pub-id pub-id-type="pmid">9014776</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mameli</surname><given-names>S</given-names></string-name>, <string-name><surname>Pisanu</surname><given-names>GM</given-names></string-name>, <string-name><surname>Sardo</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin nasal spray in fibromyalgic patients</article-title>. <source>Rheumatol Int</source><year>2014</year>;<volume>34</volume>:<fpage>1047</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/s00296-014-2953-y</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/24509894?><pub-id pub-id-type="pmid">24509894</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dworkin</surname><given-names>RH</given-names></string-name>, <string-name><surname>Turk</surname><given-names>DC</given-names></string-name>, <string-name><surname>Farrar</surname><given-names>JT</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Core outcome measures for chronic pain clinical trials: IMMPACT recommendations</article-title>. <source>Pain</source><year>2005</year>;<volume>113</volume>:<fpage>9</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2004.09.012</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15621359?><pub-id pub-id-type="pmid">15621359</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alfvén</surname><given-names>G</given-names></string-name></person-group>. <article-title>Plasma oxytocin in children with recurrent abdominal pain</article-title>. <source>J Pediatr Gastroenterol Nutr</source><year>2004</year>;<volume>38</volume>:<fpage>513</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/00005176-200405000-00010</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15097440?><pub-id pub-id-type="pmid">15097440</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alfvén</surname><given-names>G</given-names></string-name>, <string-name><surname>de la Torre</surname><given-names>B</given-names></string-name>, <string-name><surname>Uvnäs-Moberg</surname><given-names>K</given-names></string-name></person-group>. <article-title>Depressed concentrations of oxytocin and cortisol in children with recurrent abdominal pain of non-organic origin</article-title>. <source>Acta Paediatr</source><year>1994</year>;<volume>83</volume>:<fpage>1076</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.1994.tb12989.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/7841708?><pub-id pub-id-type="pmid">7841708</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Domes</surname><given-names>G</given-names></string-name>, <string-name><surname>Heinrichs</surname><given-names>M</given-names></string-name>, <string-name><surname>Gläscher</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin attenuates amygdala responses to emotional faces regardless of valence</article-title>. <source>Biol Psychiatry</source><year>2007</year>;<volume>62</volume>:<fpage>1187</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2007.03.025</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/17617382?><pub-id pub-id-type="pmid">17617382</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirsch</surname><given-names>P</given-names></string-name>, <string-name><surname>Esslinger</surname><given-names>C</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin modulates neural circuitry for social cognition and fear in humans</article-title>. <source>J Neurosci</source><year>2005</year>;<volume>25</volume>:<fpage>11489</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3984-05.2005</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16339042?><pub-id pub-id-type="pmid">16339042</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodrigues</surname><given-names>SM</given-names></string-name>, <string-name><surname>Saslow</surname><given-names>LR</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocin receptor genetic variation relates to empathy and stress reactivity in humans</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2009</year>;<volume>106</volume>:<fpage>21437</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0909579106</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/19934046?><pub-id pub-id-type="pmid">19934046</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>FS</given-names></string-name>, <string-name><surname>Kumsta</surname><given-names>R</given-names></string-name>, <string-name><surname>von Dawans</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Common oxytocin receptor gene (OXTR) polymorphism and social support interact to reduce stress in humans</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2011</year>;<volume>108</volume>:<fpage>19937</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1113079108</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22123970?><pub-id pub-id-type="pmid">22123970</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maixner</surname><given-names>W</given-names></string-name>, <string-name><surname>Fillingim</surname><given-names>RB</given-names></string-name>, <string-name><surname>Williams</surname><given-names>DA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Overlapping chronic pain conditions: implications for diagnosis and classification</article-title>. <source>J Pain</source><year>2016</year>;<volume>17</volume>:<fpage>T93</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2016.06.002</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27586833?><pub-id pub-id-type="pmid">27586833</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name><surname>Williams</surname><given-names>JB</given-names></string-name></person-group>. <article-title>The phq‐9</article-title>. <source>J Gen Intern Med</source><year>2001</year>;<volume>16</volume>:<fpage>606</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">11556941</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiMatteo</surname><given-names>MR</given-names></string-name>, <string-name><surname>Lepper</surname><given-names>HS</given-names></string-name>, <string-name><surname>Croghan</surname><given-names>TW</given-names></string-name></person-group>. <article-title>Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence</article-title>. <source>Arch Intern Med</source><year>2000</year>;<volume>160</volume>:<fpage>2101</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.160.14.2101</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/10904452?><pub-id pub-id-type="pmid">10904452</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kehoe</surname><given-names>R</given-names></string-name>, <string-name><surname>Wu</surname><given-names>SY</given-names></string-name>, <string-name><surname>Leske</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparing self-reported and physician-reported medical history</article-title>. <source>Am J Epidemiol</source><year>1994</year>;<volume>139</volume>:<fpage>813</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a117078</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/8178794?><pub-id pub-id-type="pmid">8178794</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Treede</surname><given-names>R-D</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>TS</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>JN</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neuropathic pain: redefinition and a grading system for clinical and research purposes</article-title>. <source>Neurology</source><year>2008</year>;<volume>70</volume>:<fpage>1630</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000282763.29778.59</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18003941?><pub-id pub-id-type="pmid">18003941</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bouhassira</surname><given-names>D</given-names></string-name>, <string-name><surname>Attal</surname><given-names>N</given-names></string-name>, <string-name><surname>Alchaar</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)</article-title>. <source>Pain</source><year>2005</year>;<volume>114</volume>:<fpage>29</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2004.12.010</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15733628?><pub-id pub-id-type="pmid">15733628</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vleeming</surname><given-names>A</given-names></string-name>, <string-name><surname>Albert</surname><given-names>HB</given-names></string-name>, <string-name><surname>Ostgaard</surname><given-names>HC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>European guidelines for the diagnosis and treatment of pelvic girdle pain</article-title>. <source>Eur Spine J</source><year>2008</year>;<volume>17</volume>:<fpage>794</fpage>–<lpage>819</lpage>. <pub-id pub-id-type="doi">10.1007/s00586-008-0602-4</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/18259783?><pub-id pub-id-type="pmid">18259783</pub-id></mixed-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Association AP</collab></person-group>. <source>Diagnostic and statistical manual of mental disorders (DSM-5)</source>. <edition>5th edn</edition>. <publisher-loc>Arlington, VA</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>, <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Turk</surname><given-names>DC</given-names></string-name>, <string-name><surname>Melzack</surname><given-names>R</given-names></string-name></person-group>. <source>Handbook of pain assessment</source>. <edition>3rd edn</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Guilford Press</publisher-name>, <year>2011</year>.</mixed-citation>
              </ref>
              <ref id="R51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name><surname>Hopewell</surname><given-names>S</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title>. <source>Int J Surg</source><year>2012</year>;<volume>10</volume>:<fpage>28</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijsu.2011.10.001</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22036893?><pub-id pub-id-type="pmid">22036893</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>PLoS Med</source><year>2010</year>;<volume>7</volume>:<elocation-id>e1000251</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1000251</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/20352064?><pub-id pub-id-type="pmid">20352064</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riley</surname><given-names>JL</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Wise</surname><given-names>EA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A meta-analytic review of pain perception across the menstrual cycle</article-title>. <source>Pain</source><year>1999</year>;<volume>81</volume>:<fpage>225</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3959(98)00258-9</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/10431710?><pub-id pub-id-type="pmid">10431710</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guastella</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Hickie</surname><given-names>IB</given-names></string-name>, <string-name><surname>McGuinness</surname><given-names>MM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research</article-title>. <source>Psychoneuroendocrinology</source><year>2013</year>;<volume>38</volume>:<fpage>612</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2012.11.019</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23265311?><pub-id pub-id-type="pmid">23265311</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Born</surname><given-names>J</given-names></string-name>, <string-name><surname>Lange</surname><given-names>T</given-names></string-name>, <string-name><surname>Kern</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sniffing neuropeptides: a transnasal approach to the human brain</article-title>. <source>Nat Neurosci</source><year>2002</year>;<volume>5</volume>:<fpage>514</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nn849</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11992114?><pub-id pub-id-type="pmid">11992114</pub-id></mixed-citation>
              </ref>
              <ref id="R56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Ijzendoorn</surname><given-names>MH</given-names></string-name>, <string-name><surname>Bhandari</surname><given-names>R</given-names></string-name>, <string-name><surname>van der Veen</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Elevated Salivary Levels of Oxytocin Persist More than 7 h after Intranasal Administration</article-title>. <source>Front Neurosci</source><year>2012</year>;<volume>6</volume>:<elocation-id>174</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnins.2012.00174</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23233832?><pub-id pub-id-type="pmid">23233832</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Light</surname><given-names>KC</given-names></string-name>, <string-name><surname>Grewen</surname><given-names>KM</given-names></string-name>, <string-name><surname>Amico</surname><given-names>JA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oxytocinergic activity is linked to lower blood pressure and vascular resistance during stress in postmenopausal women on estrogen replacement</article-title>. <source>Horm Behav</source><year>2005</year>;<volume>47</volume>:<fpage>540</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2004.12.010</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15811355?><pub-id pub-id-type="pmid">15811355</pub-id></mixed-citation>
              </ref>
              <ref id="R58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cleeland</surname><given-names>CS</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>KM</given-names></string-name></person-group>. <article-title>Pain assessment: global use of the brief pain inventory</article-title>. <source>Ann Acad Med Singap</source><year>1994</year>;<volume>23</volume>:<fpage>129</fpage>–<lpage>38</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/8080219?><pub-id pub-id-type="pmid">8080219</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keller</surname><given-names>S</given-names></string-name>, <string-name><surname>Bann</surname><given-names>CM</given-names></string-name>, <string-name><surname>Dodd</surname><given-names>SL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain</article-title>. <source>Clin J Pain</source><year>2004</year>;<volume>20</volume>:<fpage>309</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1097/00002508-200409000-00005</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15322437?><pub-id pub-id-type="pmid">15322437</pub-id></mixed-citation>
              </ref>
              <ref id="R60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mendoza</surname><given-names>T</given-names></string-name>, <string-name><surname>Mayne</surname><given-names>T</given-names></string-name>, <string-name><surname>Rublee</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reliability and validity of a modified brief pain inventory short form in patients with osteoarthritis</article-title>. <source>Eur J Pain</source><year>2006</year>;<volume>10</volume>:<fpage>353</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpain.2005.06.002</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16051509?><pub-id pub-id-type="pmid">16051509</pub-id></mixed-citation>
              </ref>
              <ref id="R61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname><given-names>G</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>MP</given-names></string-name>, <string-name><surname>Thornby</surname><given-names>JI</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Validation of the brief pain inventory for chronic nonmalignant pain</article-title>. <source>J Pain</source><year>2004</year>;<volume>5</volume>:<fpage>133</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2003.12.005</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/15042521?><pub-id pub-id-type="pmid">15042521</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kapstad</surname><given-names>H</given-names></string-name>, <string-name><surname>Rokne</surname><given-names>B</given-names></string-name>, <string-name><surname>Stavem</surname><given-names>K</given-names></string-name></person-group>. <article-title>Psychometric properties of the brief pain inventory among patients with osteoarthritis undergoing total hip replacement surgery</article-title>. <source>Health Qual Life Outcomes</source><year>2010</year>;<volume>8</volume>:<elocation-id>148</elocation-id>. <pub-id pub-id-type="doi">10.1186/1477-7525-8-148</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21143926?><pub-id pub-id-type="pmid">21143926</pub-id></mixed-citation>
              </ref>
              <ref id="R63">
                <label>63</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Cleeland</surname><given-names>C</given-names></string-name></person-group>. <source>The brief pain inventory: user guide</source>. <publisher-loc>University of Texas, TX</publisher-loc>: <publisher-name>M. D. Anderson Cancer Center</publisher-name>, <year>2009</year>.</mixed-citation>
              </ref>
              <ref id="R64">
                <label>64</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Lovibond</surname><given-names>P</given-names></string-name></person-group>. <source>Manual for the depression anxiety stress scales</source>. <publisher-loc>Sydney</publisher-loc>: <publisher-name>Sydney Psychology edition</publisher-name>, <year>1995</year>.</mixed-citation>
              </ref>
              <ref id="R65">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brown</surname><given-names>TA</given-names></string-name>, <string-name><surname>Chorpita</surname><given-names>BF</given-names></string-name>, <string-name><surname>Korotitsch</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Psychometric properties of the depression anxiety stress scales (DASS) in clinical samples</article-title>. <source>Behav Res Ther</source><year>1997</year>;<volume>35</volume>:<fpage>79</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/s0005-7967(96)00068-x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/9009048?><pub-id pub-id-type="pmid">9009048</pub-id></mixed-citation>
              </ref>
              <ref id="R66">
                <label>66</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Hays</surname><given-names>RD</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>A</given-names></string-name></person-group>. <source>Sleep measures</source>, <year>1992</year>.</mixed-citation>
              </ref>
              <ref id="R67">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hurst</surname><given-names>H</given-names></string-name>, <string-name><surname>Bolton</surname><given-names>J</given-names></string-name></person-group>. <article-title>Assessing the clinical significance of change scores recorded on subjective outcome measures</article-title>. <source>J Manipulative Physiol Ther</source><year>2004</year>;<volume>27</volume>:<fpage>26</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmpt.2003.11.003</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/14739871?><pub-id pub-id-type="pmid">14739871</pub-id></mixed-citation>
              </ref>
              <ref id="R68">
                <label>68</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dunkl</surname><given-names>PR</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>AG</given-names></string-name>, <string-name><surname>McConnell</surname><given-names>GG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Responsiveness of fibromyalgia clinical trial outcome measures</article-title>. <source>J Rheumatol</source><year>2000</year>;<volume>27</volume>:<fpage>2683</fpage>–<lpage>91</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11093454?><pub-id pub-id-type="pmid">11093454</pub-id></mixed-citation>
              </ref>
              <ref id="R69">
                <label>69</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farrar</surname><given-names>JT</given-names></string-name>, <string-name><surname>Young</surname><given-names>JP</given-names></string-name>, <string-name><surname>LaMoreaux</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale</article-title>. <source>Pain</source><year>2001</year>;<volume>94</volume>:<fpage>149</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3959(01)00349-9</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11690728?><pub-id pub-id-type="pmid">11690728</pub-id></mixed-citation>
              </ref>
              <ref id="R70">
                <label>70</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sullivan</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bishop</surname><given-names>SR</given-names></string-name>, <string-name><surname>Pivik</surname><given-names>J</given-names></string-name></person-group>. <article-title>The pain catastrophizing scale: development and validation</article-title>. <source>Psychol Assess</source><year>1995</year>;<volume>7</volume>:<elocation-id>524</elocation-id>.</mixed-citation>
              </ref>
              <ref id="R71">
                <label>71</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Devilly</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Borkovec</surname><given-names>TD</given-names></string-name></person-group>. <article-title>Psychometric properties of the credibility/expectancy questionnaire</article-title>. <source>J Behav Ther Exp Psychiatry</source><year>2000</year>;<volume>31</volume>:<fpage>73</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/s0005-7916(00)00012-4</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11132119?><pub-id pub-id-type="pmid">11132119</pub-id></mixed-citation>
              </ref>
              <ref id="R72">
                <label>72</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mayer</surname><given-names>TG</given-names></string-name>, <string-name><surname>Neblett</surname><given-names>R</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The development and psychometric validation of the central sensitization inventory</article-title>. <source>Pain Pract</source><year>2012</year>;<volume>12</volume>:<fpage>276</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1111/j.1533-2500.2011.00493.x</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21951710?><pub-id pub-id-type="pmid">21951710</pub-id></mixed-citation>
              </ref>
              <ref id="R73">
                <label>73</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neblett</surname><given-names>R</given-names></string-name>, <string-name><surname>Hartzell</surname><given-names>MM</given-names></string-name>, <string-name><surname>Mayer</surname><given-names>TG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Establishing clinically relevant severity levels for the central sensitization inventory</article-title>. <source>Pain Pract</source><year>2017</year>;<volume>17</volume>:<fpage>166</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/papr.12440</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26989894?><pub-id pub-id-type="pmid">26989894</pub-id></mixed-citation>
              </ref>
              <ref id="R74">
                <label>74</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nasr-Esfahani</surname><given-names>M</given-names></string-name>, <string-name><surname>Jarrell</surname><given-names>J</given-names></string-name></person-group>. <article-title>Cotton-tipped applicator test: validity and reliability in chronic pelvic pain</article-title>. <source>Am J Obstet Gynecol</source><year>2013</year>;<volume>208</volume>:<fpage>52 e1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2012.11.005</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23159690?><pub-id pub-id-type="pmid">23159690</pub-id></mixed-citation>
              </ref>
              <ref id="R75">
                <label>75</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katz</surname><given-names>NP</given-names></string-name></person-group>. <article-title>The measurement of symptoms and side effects in clinical trials of chronic pain</article-title>. <source>Contemp Clin Trials</source><year>2012</year>;<volume>33</volume>:<fpage>903</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2012.04.008</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/22561389?><pub-id pub-id-type="pmid">22561389</pub-id></mixed-citation>
              </ref>
              <ref id="R76">
                <label>76</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Kristjanson</surname><given-names>L</given-names></string-name>, <string-name><surname>Pickstock</surname><given-names>S</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>K</given-names></string-name></person-group>. <source>Development and testing of the revised symptom assessment scale (SAS): final report</source>. <publisher-loc>Perth, Western Australia</publisher-loc>: <publisher-name>Edith Cowan University</publisher-name>, <year>1999</year>.</mixed-citation>
              </ref>
              <ref id="R77">
                <label>77</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O'Brien</surname><given-names>PC</given-names></string-name>, <string-name><surname>Fleming</surname><given-names>TR</given-names></string-name></person-group>. <article-title>A multiple testing procedure for clinical trials</article-title>. <source>Biometrics</source><year>1979</year>;<volume>35</volume>:<fpage>549</fpage>–<lpage>56</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/497341?><pub-id pub-id-type="pmid">497341</pub-id></mixed-citation>
              </ref>
              <ref id="R78">
                <label>78</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>idák</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Rectangular confidence regions for the means of multivariate normal distributions</article-title>. <source>J Am Stat Assoc</source><year>1967</year>;<volume>62</volume>:<fpage>626</fpage>–<lpage>33</lpage>.</mixed-citation>
              </ref>
              <ref id="R79">
                <label>79</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Montori</surname><given-names>VM</given-names></string-name>, <string-name><surname>Guyatt</surname><given-names>GH</given-names></string-name></person-group>. <article-title>Intention-to-treat principle</article-title>. <source>CMAJ</source><year>2001</year>;<volume>165</volume>:<fpage>1339</fpage>–<lpage>41</lpage>.<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/11760981?><pub-id pub-id-type="pmid">11760981</pub-id></mixed-citation>
              </ref>
              <ref id="R80">
                <label>80</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Tabachnick</surname><given-names>BG</given-names></string-name>, <string-name><surname>Fidell</surname><given-names>LS</given-names></string-name></person-group>. <source>Using multivariate statistics</source>. <edition>6th edn</edition>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Pearson</publisher-name>, <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="R81">
                <label>81</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Little</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>DB</given-names></string-name></person-group>. <source>Statistical analysis with missing data. statistical analysis with missing data, 2nd ED, by RJA little and DB Rubin Wiley series in probability and stistics</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Wiley</publisher-name>, <year>2002</year>,: <fpage>1</fpage><comment>2002</comment>.</mixed-citation>
              </ref>
              <ref id="R82">
                <label>82</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Harrell</surname><given-names>F</given-names></string-name></person-group>. <source>Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2001</year>.</mixed-citation>
              </ref>
              <ref id="R83">
                <label>83</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Ellenberg</surname><given-names>SS</given-names></string-name>, <string-name><surname>Fleming</surname><given-names>TR</given-names></string-name>, <string-name><surname>DeMets</surname><given-names>DL</given-names></string-name></person-group>. <source>Data monitoring committees in clinical trials: a practical perspective</source>. <publisher-loc>West Sussex, England</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>, <year>2002</year>.</mixed-citation>
              </ref>
              <ref id="R84">
                <label>84</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>MacDonald</surname><given-names>E</given-names></string-name>, <string-name><surname>Dadds</surname><given-names>MR</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research</article-title>. <source>Psychoneuroendocrinology</source><year>2011</year>;<volume>36</volume>:<fpage>1114</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2011.02.015</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21429671?><pub-id pub-id-type="pmid">21429671</pub-id></mixed-citation>
              </ref>
              <ref id="R85">
                <label>85</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Treweek</surname><given-names>S</given-names></string-name>, <string-name><surname>Lockhart</surname><given-names>P</given-names></string-name>, <string-name><surname>Pitkethly</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Methods to improve recruitment to randomised controlled trials: cochrane systematic review and meta-analysis</article-title>. <source>BMJ Open</source><year>2013</year>;<volume>3</volume><pub-id pub-id-type="doi">10.1136/bmjopen-2012-002360</pub-id><?supplied-pmid 23396504?><pub-id pub-id-type="pmid">23396504</pub-id></mixed-citation>
              </ref>
              <ref id="R86">
                <label>86</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caldwell</surname><given-names>PHY</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>S</given-names></string-name>, <string-name><surname>Tan</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Strategies for increasing recruitment to randomised controlled trials: systematic review</article-title>. <source>PLoS Med</source><year>2010</year>;<volume>7</volume>:<elocation-id>e1000368</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1000368</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/21085696?><pub-id pub-id-type="pmid">21085696</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
